Concepedia

Publication | Open Access

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

DOIFull Paper Access

12

Citations

35

References

2024

Year

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett, Ines Figueiredo, Bora Gürel, Christina Guo, Verena Brucklacher-Waldert, H. Lorraine Thompson, Jude Akinwale,
Clinical Cancer Research

Abstract

CB307 is a first-in-class immunotherapeutic that triggers potent PSMA-dependent T-cell activation, thereby alleviating toxicologic concerns against unrestricted CD137 agonism.

References

YearCitations

Page 1